Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
NCT Number: NCT05596071
The purpose of this study was to investigate whether perioperative use of low doses of opioids could reduce postoperative delirium .
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
Hangzhou, Zhejiang, 310022, China
Postoperative delirium (POD) is a common postoperative complication of the elderly caused by a variety of factors. POD is an acute neuropsychiatric disorder characterized by disturbance of attention consciousness and cognitive function fluctuation, and more than 40% of elderly patients have symptoms of hypoactivity POD.The incidence of POD is as high as 17% to 61% in patients with neurocognitive impairment and patients undergoing complex or emergency surgery, which usually occurs between 1 and 3 days after surgery. POD will lead to prolonged hospital stay, functional impairment and even death. How to prevent and treat POD is an urgent clinical problem to be solved at present.
Opiates are commonly used perioperative sedatives and analgesics, which may be associated with the occurrence of postoperative POD in elderly patients and increase the risk of POD. It is not clear whether perioperative use of low doses of opioids could reduces the incidence of POD in elderly patients. In this study, reducing-opioids anesthesia was defined as the use of 1/3 of the conventional opioid dose to observe whether reducing-opioids anesthesia affected the incidence of POD in elderly patients undergoing gastric cancer surgery
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml
Other names: Sufentanil
Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs
Other names: Ropivacaine
Intraoperative and postoperative analgesia
Time frame: 3 days after surgery
confusion assessment method for the ICU(CAM-ICU)
Time frame: 3 days after surgery
Richmond agitation and sedation scale(RASS), the RASS score was divided into 10 sedation scales, ranging from +4 to -5, representing the patient's degree from "aggressive" to "unconscious," with each score corresponding to a state of consciousness. When the RASS score was ≥-3, the CAM-ICU assessment was performed.
Time frame: 3 days after surgery
VAS is a scale of 11 numbers ranging from 0 to 10, with 0 representing no pain and 10 representing the most pain. Patients choose one of the 11 numbers to represent the pain level according to their own pain.
0: no pain;
Less than 3 points: mild pain, tolerable;
4-6 points: the patient's pain and affect sleep, still tolerable;
7-10: Patients have increasing pain, pain is unbearable, affect appetite, affect sleep.
Time frame: 3 days after surgery
Nausea and vomiting
Time frame: 3 days after surgery
Hypertension or hypotension was defined as an increase or decrease in mean arterial pressure of more than 30% at baseline
Zhejiang Cancer Hospital
Other
Whether Opioids Are Factor That Induced Postoperative Delirium?
Acronym: POD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07351474
Confusion, Delirium
Nanjing, Jiangsu, China
View Trial DetailsNCT05823844
Confusion, Delirium
New York, United States
View Trial DetailsNCT07714928
Cognition Disorders, Cognitive Dysfunction
Örebro, Sweden
View Trial DetailsNCT05574400
Alzheimer Disease, Brain Diseases
Ann Arbor, Michigan, United States
View Trial Details